Invention Grant
US07988974B2 Antifusogenic proteins comprising human immunodeficiency virus type 1 (HIV-1) gp41 DP-178 polypeptide variants and a macromolecular carrier
失效
包含人免疫缺陷病毒1型（HIV-1）gp41 DP-178多肽变体和大分子载体的抗发育蛋白
- Patent Title: Antifusogenic proteins comprising human immunodeficiency virus type 1 (HIV-1) gp41 DP-178 polypeptide variants and a macromolecular carrier
- Patent Title (中): 包含人免疫缺陷病毒1型（HIV-1）gp41 DP-178多肽变体和大分子载体的抗发育蛋白
-
Application No.: US11253274Application Date: 2005-10-17
-
Publication No.: US07988974B2Publication Date: 2011-08-02
- Inventor: Michael L. Greenberg , Thomas James Matthews , Chin-Ho Chen
- Applicant: Michael L. Greenberg , Thomas James Matthews , Chin-Ho Chen
- Applicant Address: US NC Durham
- Assignee: Duke University
- Current Assignee: Duke University
- Current Assignee Address: US NC Durham
- Agency: Jones Day
- Main IPC: A61K39/21
- IPC: A61K39/21 ; A61K39/00 ; A61K39/385
Abstract:
The present invention relates to fusion peptides which exhibit potent anti-retroviral activity. The fusion peptides of the invention comprise a macromolecular carrier group fused to a gp41-derived DP178 (SEQ ID NO:1) peptide corresponding to amino acids 638 to 673 of the HIV-1LA1 gp41 protein, or fragments, analogs or homologs of DP178. The invention further relates to the uses of such fusion peptides as inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells.
Public/Granted literature
- US20070202123A1 Fusion proteins comprising DP-178 and other viral fusion inhibitor peptides useful for treating aids Public/Granted day:2007-08-30
Information query
